Danaher announced that its President and CEO, Rainer Blair, will comment tomorrow on the company’s fourth quarter 2023 performance in a presentation at the J.P. Morgan Healthcare Conference at 2:15 p.m. ET. For the fourth quarter 2023, estimated revenues are anticipated to decrease in the low-double digit percent range year-over-year. Estimated non-GAAP core revenue for the fourth quarter of 2023 is expected to decline in the low-double digit percent range, which would be above the company’s previously announced guidance of a high-teens percent decline. Estimated non-GAAP base business core revenue for the fourth quarter of 2023 is expected to decline in the mid-single digit percent range, which would be in line with the company’s previously announced guidance.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR:
- Danaher put volume heavy and directionally bearish
- Danaher initiated with a Hold at HSBC
- Codexis and Aldevron in licensing pact for Codex HiCap RNA Polymerase
- Danaher initiated with neutral view at Wolfe Research, here’s why
- Danaher initiated with neutral view at Wolfe Research
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue